Exozymes Inc. (EXOZ) — SEC Filings
Exozymes Inc. (EXOZ) — 28 SEC filings. Latest: 8-K (May 7, 2026). Includes 12 8-K, 8 S-1/A, 4 10-Q.
View Exozymes Inc. on SEC EDGAR
Overview
Exozymes Inc. (EXOZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: ExoZymes Inc. filed an 8-K on December 12, 2025, reporting an event that occurred on December 11, 2025. The filing indicates a change in the company's status or operations, though specific details of the event are not provided in this excerpt. The company, formerly Invizyne Technologies Inc., is inc
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 2 bearish, 26 neutral. The dominant filing sentiment for Exozymes Inc. is neutral.
Filing Type Overview
Exozymes Inc. (EXOZ) has filed 12 8-K, 1 424B5, 4 10-Q, 1 DEF 14A, 1 10-K, 8 S-1/A, 1 S-1 with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of EXOZ's 25 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$6,503,698 |
| EPS | N/A |
| Debt-to-Equity | 0.44 |
| Cash Position | $5,098,687 |
| Operating Margin | N/A |
| Total Assets | $7,719,049 |
| Total Debt | $2,344,627 |
Key Executives
- Michael Heltzen
- Andrew Hudders
- Aaron A. Grunfeld
Industry Context
Exozymes operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry relies heavily on venture capital and public markets for funding, especially for pre-revenue companies. Success is often tied to breakthroughs in research and successful clinical trials, making the path to commercialization uncertain and capital-intensive.
Top Tags
sec-filing (7) · amendment (5) · ipo (5) · Biotechnology (3) · Registration Statement (3) · Emerging Growth Company (3) · 8-K (2) · Synthetic Biology (2) · Going Concern (2) · Cash Burn (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $6.50M | Increased 61.6% for the nine months ended September 30, 2025, from $4.03M in 2024. |
| Cash Used in Operations | $4.53M | Increased 61.8% for the nine months ended September 30, 2025, from $2.80M in 2024. |
| Cash and Cash Equivalents | $5.10M | Decreased 47.5% from $9.72M at December 31, 2024, to September 30, 2025. |
| Total Assets | $7.72M | Decreased from $13.03M at December 31, 2024, to September 30, 2025. |
| General and Administrative Costs | $4.43M | Increased 63.3% for the nine months ended September 30, 2025, from $2.71M in 2024. |
| Research and Development Costs | $2.59M | Increased 109.5% for the nine months ended September 30, 2025, from $1.24M in 2024. |
| Common Shares Outstanding | 8,387,250 | As of September 30, 2025. |
| MDB Capital Holdings Minority Interest | 47% | As of September 30, 2025, after IPO dilution. |
| Net Cash Used in Operating Activities | $2.67M | Increased from $2.26M for six months ended June 30, 2024. |
| Grant Reimbursement Source | 98% | Percentage from the Department of Energy for six months ended June 30, 2025. |
| MDB Capital Holdings Ownership | 48% | Minority interest as of June 30, 2025, diluted from majority ownership post-IPO. |
| Outstanding Common Shares | 8,387,250 | As of August 12, 2025. |
| SEC File Number | 001-42204 | Identifies the company's filing with the SEC. |
| EIN | 83-4550057 | Employer Identification Number for tax purposes. |
| Number of director nominees | 6 | To be elected at the 2025 Annual Meeting |
Forward-Looking Statements
- {"claim":"Invizyne Technologies Inc. will complete its initial public offering (IPO) or public sale of securities within the next 12 months.","entity":"Invizyne Technologies Inc.","targetDate":"February 9, 2025","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Exozymes Inc. (EXOZ)?
Exozymes Inc. has 28 recent SEC filings from Feb 2024 to May 2026, including 12 8-K, 8 S-1/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EXOZ filings?
Across 28 filings, the sentiment breakdown is: 2 bearish, 26 neutral. The dominant sentiment is neutral.
Where can I find Exozymes Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Exozymes Inc. (EXOZ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Exozymes Inc.?
Key financial highlights from Exozymes Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EXOZ?
The investment thesis for EXOZ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Exozymes Inc.?
Key executives identified across Exozymes Inc.'s filings include Michael Heltzen, Andrew Hudders, Aaron A. Grunfeld.
What are the main risk factors for Exozymes Inc. stock?
Of EXOZ's 25 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Exozymes Inc.?
Recent forward-looking statements from Exozymes Inc. include guidance on {"claim":"Invizyne Technologies Inc. will complete its initial public offering (IPO) or public sale of securities within.